BDX - Becton, Dickinson and Company
NYSE
->
Healthcare
->
Medical Instruments & Supplies
Franklin Lakes,
United States
Type: Equity
BDX price evolution
BDX
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4487 | $2394 | $1234 | |
| Short term investments | $851 | $827 | $2 | |
| Net receivables | $3033 | $2596 | $2559 | $2267 |
| Inventory | $3843 | $3255 | $3229 | $3304 |
| Total current assets | $10468 | $12207 | $10340 | $8156 |
| Long term investments | ||||
| Property, plant & equipment | $6821 | $6518 | $6591 | $6647 |
| Goodwill & intangible assets | $34456 | $34826 | $35211 | |
| Total noncurrent assets | $43375 | $43817 | $44118 | |
| Total investments | $851 | $827 | $2 | |
| Total assets | $57286 | $55582 | $54157 | $52274 |
| Current liabilities | ||||
| Accounts payable | $5413 | $5311 | $5524 | |
| Deferred revenue | ||||
| Short long term debt | $1192 | $2016 | $2016 | |
| Total current liabilities | $8947 | $6605 | $7327 | $7540 |
| Long term debt | $17940 | $18131 | $15995 | $14094 |
| Total noncurrent liabilities | $23109 | $21183 | $19402 | |
| Total debt | $19323 | $18011 | $16110 | |
| Total liabilities | $31375 | $29714 | $28510 | $26942 |
| Shareholders' equity | ||||
| Retained earnings | $16015 | $15802 | $15540 | |
| Other shareholder equity | $25911 | -$1558 | -$1510 | -$1515 |
| Total shareholder equity | $25868 | $25647 | $25332 | |
| (in millions $) | 30 Oct 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1481 | $1159 | $2392 | $2917 |
| Short term investments | $8 | $8 | $12 | $20 |
| Net receivables | $2534 | $2191 | $2497 | $2398 |
| Inventory | $3273 | $3224 | $2866 | $2743 |
| Total current assets | $8676 | $8141 | $8838 | $8969 |
| Long term investments | ||||
| Property, plant & equipment | $6557 | $6012 | $6393 | $5923 |
| Goodwill & intangible assets | $35470 | $36931 | $36684 | $37433 |
| Total noncurrent assets | $44104 | $44793 | $45028 | $45043 |
| Total investments | $8 | $8 | $12 | $20 |
| Total assets | $52780 | $52934 | $53866 | $54012 |
| Current liabilities | ||||
| Accounts payable | $4245 | $4304 | $4736 | $3993 |
| Deferred revenue | ||||
| Short long term debt | $1141 | $2179 | $500 | $707 |
| Total current liabilities | $6641 | $7811 | $6626 | $5836 |
| Long term debt | $14738 | $13886 | $17110 | $17224 |
| Total noncurrent liabilities | $20343 | $19841 | $23563 | $24411 |
| Total debt | $15879 | $16065 | $17610 | $17931 |
| Total liabilities | $26984 | $27652 | $30189 | $30247 |
| Shareholders' equity | ||||
| Retained earnings | $15535 | $15157 | $13826 | $12791 |
| Other shareholder equity | $25796 | -$1488 | -$2088 | -$2548 |
| Total shareholder equity | $25796 | $25282 | $23677 | $23765 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4990 | $5045 | $4706 | |
| Cost of revenue | $2683 | $2741 | $2679 | |
| Gross Profit | $2307 | $2304 | $2027 | |
| Operating activities | ||||
| Research & development | $299 | $299 | $290 | |
| Selling, general & administrative | $1196 | $1193 | $1213 | |
| Total operating expenses | $1705 | $1570 | $1589 | |
| Operating income | $602 | $734 | $438 | |
| Income from continuing operations | ||||
| EBIT | $637 | $758 | $469 | |
| Income tax expense | $13 | $96 | $77 | |
| Interest expense | $137 | $125 | $111 | |
| Net income | ||||
| Net income | $487 | $537 | $281 | |
| Income (for common shares) | $487 | $537 | $281 | |
| (in millions $) | 30 Oct 2023 | 31 Jan 2023 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $19372 | $17117 | ||
| Cost of revenue | $9540 | |||
| Gross Profit | $8170 | $7577 | ||
| Operating activities | ||||
| Research & development | $1096 | |||
| Selling, general & administrative | $4325 | |||
| Total operating expenses | $5732 | $6093 | ||
| Operating income | $1484 | |||
| Income from continuing operations | ||||
| EBIT | $1513 | |||
| Income tax expense | $132 | $111 | ||
| Interest expense | -$403 | $528 | ||
| Net income | ||||
| Net income | $1424 | $874 | ||
| Income (for common shares) | $767 | |||
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $487 | $537 | $281 | |
| Operating activities | ||||
| Depreciation | $568 | $571 | $561 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $53 | $60 | $83 | |
| Total cash flows from operations | $1265 | $514 | $841 | |
| Investing activities | ||||
| Capital expenditures | -$179 | -$134 | -$116 | |
| Investments | -$15 | -$815 | ||
| Total cash flows from investing | -$5514 | -$288 | -$1056 | -$233 |
| Financing activities | ||||
| Dividends paid | -$1100 | -$275 | -$275 | -$275 |
| Sale and purchase of stock | -$500 | |||
| Net borrowings | $1403 | $1972 | ||
| Total cash flows from financing | $2087 | $1120 | $1705 | -$862 |
| Effect of exchange rate | $4 | -$4 | -$3 | $7 |
| Change in cash and equivalents | $375 | $2093 | $1160 | -$247 |
| (in millions $) | 30 Oct 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $1779 | $2092 | $874 | |
| Operating activities | ||||
| Depreciation | $2229 | $2273 | $2154 | |
| Business acquisitions & disposals | -$2070 | -$508 | -$164 | |
| Stock-based compensation | $265 | $252 | $296 | |
| Total cash flows from operations | $2634 | $4647 | $3539 | |
| Investing activities | ||||
| Capital expenditures | -$973 | -$1231 | -$810 | |
| Investments | ||||
| Total cash flows from investing | -$716 | -$3231 | -$1880 | -$1232 |
| Financing activities | ||||
| Dividends paid | -$1114 | -$1082 | -$1048 | -$1026 |
| Sale and purchase of stock | -$500 | -$1750 | $2917 | |
| Net borrowings | -$78 | -$243 | -$1760 | |
| Total cash flows from financing | -$1957 | -$591 | -$3306 | $22 |
| Effect of exchange rate | $5 | -$45 | $15 | -$3 |
| Change in cash and equivalents | $1851 | -$1233 | -$525 | $2326 |
News
|
Hologic Post Q4 Earnings Miss: Time to Buy, Hold or Sell the Stock?
Zacks
8 Nov 2024
|
|
Decoding Steris PLC (STE): A Strategic SWOT Insight
GuruFocus.com · via Yahoo Finance
8 Nov 2024
|
|
Global Medical Tech Becton, Dickinson Expects Lower China Sales, Bioscience And...
Benzinga · via Yahoo Finance
7 Nov 2024
|
|
BDX Stock Gains Following Q4 Earnings Beat and Higher Margins
Zacks
7 Nov 2024
|
|
Global Medical Tech Becton, Dickinson Expects Lower China Sales, Bioscience And...
Benzinga · via AOL
7 Nov 2024
|
|
Can Sustained Product Demand Drive BDX Stock Before Q4 Earnings?
Zacks
4 Nov 2024
|
|
Should You Buy, Sell or Hold McKesson Before Q2 Earnings?
Zacks
4 Nov 2024
|
|
Edwards Lifesciences Completes Sale of Critical Care
Los Angeles Times
3 Nov 2024
|
|
Becton, Dickinson and Company (BDX): Expanding Innovations in Medical Technology
Insider Monkey · via Yahoo Finance
3 Nov 2024
|
|
Is Becton, Dickinson and Company (NYSE:BDX) The Most Popular Stock Among Mutual...
Insider Monkey · via Yahoo Finance
13 Oct 2024
|
Fundamentals
| Market cap | $65.16B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 289.04M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.05 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.17 |
| Quick ratio | 0.74 |